Published by Iain Gilbert on 1st September 2026
(Sharecast News) - Drugmaker Astrazeneca delivered a pair of lung‑cancer updates on Tuesday, with the group completing a global licensing deal for Zegfrovy (sunvozertinib) while also reporting positive Phase III data for a Tagrisso-Orpathys combination in first‑line MET‑overexpressing EGFR‑mutated disease.